ClinicalTrials.gg
RecruitingNCT06434610Updated May 5, 2026

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

A Phase 2 interventional study of B013 and Paclitaxel in Platinum-resistant Recurrent Ovarian Cancer, sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd. Recruiting at 17 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 395 studies in Ovarian Neoplasms with a site in China — 201 open to participants now, 233 under way, 36 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
153rd of 322
90 · median 83
Started
2024
with 53 others
Phase 2
107 of 395
54 open now
Primary completion
2026-12
later than 97 of 232 live
Registered
257th of 395
by date

Among the 395 studies in Ovarian Neoplasms with a site in China, this one is the 153rd largest by planned enrollment of the 322 interventional ones that give a count, is one of 54 that started in 2024, is one of 107 in phase 2, reaches primary completion later than 97 of the 232 other live ones, and was the 257th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

201 of the 395 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

196 more — sign in →

All 201 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.

03

Conditions studied

  • Platinum-resistant Recurrent Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who voluntarily participate in this study and sign form;
  2. Ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by histopathological examination and meeting the criteria for platinum resistance recurrence;
  3. performance status of 0 or 1;
  4. Expected survival > 12 weeks;
  5. The subject has at least one ;
  6. Normal function of major organs;
  7. The fertile subjects agree to use reliable from signing the informed consent to at least 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received prescribed treatment previously;
  2. Subjects who are still using anti-tumor traditional Chinese patent medicines at the time of signing ;
  3. Subjects with known central nervous system and multiple bone metastasis;
  4. Subjects who had clinical symptoms of pleural effusion, pericardial effusion or ascites before randomization and needed puncture drainage, or had received puncture drainage within the previous 2 weeks;
  5. Have a history of other malignant tumors within 5 years before signing the informed consent;
  6. Subjects with prescribed cardiovascular diseases;
  7. Subjects with infections requiring intravenous antibiotic infusion within 2 weeks prior to randomization;
  8. Had severe lung disease before randomization;
  9. Before randomization, the peripheral nerve toxicity of previous anti-tumor treatment was > grade 2, and other reversible toxicity was > grade 1;
  10. Subjects who had undergone surgery within 28 days prior to randomization and did not recover from adverse effects of surgery;
  11. Subjects who participated in clinical trials within 30 days prior to randomization and received other unmarketed drugs;
  12. Subjects who are known to be allergic to any component of B013 or paclitaxel.
  13. Subjects with a known history of substance abuse, alcohol or drug use; Subjects with a known history of neurological or psychiatric disorders;
  14. Female subjects who are pregnant or breastfeeding;
  15. Other situations determined by the researchers and/or sponsors as unsuitable for participation in this trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    B013

    Drug: B013 · Drug: Paclitaxel

  • Placebo comparator
    Placebo

    Drug: Paclitaxel · Drug: Placebo

Interventions

  • DrugB013

    B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.

  • Paclitaxel: 80 mg/m\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.

  • DrugPlacebo

    Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    From the date of randomization to the date of progression disease or death , whichever occurred first.

    Time frame: Approximately 2 years

Secondary outcomes

  1. Objective response rate (ORR)

    Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1.

    Time frame: Approximately 2 years

  2. Disease control rate (DCR)

    DCR was defined as the percentage of participants who have achieved complete response, partial response and stable disease.

    Time frame: Approximately 2 years

  3. Duration of remission (DOR)

    DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause.

    Time frame: Approximately 5 years

  4. Overall Survival (OS)

    Determination of the overall survival times of all participants.

    Time frame: Approximately 2 years

  5. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    The incidence of adverse event (regardless of its relationship to study drug) will be classified using MedDRA and the severity of each adverse event will be graded using NCI CTCAE v5.0.

    Time frame: Approximately 5 years

07

Study locations

17 of 17 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 29 months is below that.

Counting every sponsor, half of 345 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2024
First posted
May 30, 2024
StartActual
Jul 11, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06434610
Lead sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Responsible party
Sponsor
First posted
May 30, 2024
Start date
Jul 11, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Xiaohua Wu
Contact
JJYIN555@163.com
0086-021-64175590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion